Relapsed or Refractory Acute Myeloid Leukemia research hub

A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML).

This study is testing a new medicine, Pivekimab Sunirine, in children and teenagers with a type of blood cancer called Acute Myeloid Leukaemia (AML) that has come back or hasn't responded to other treatments. The main aim is to see if the medicine is safe and how it moves through the body.